Theresa Case, DO
Pulmonary Disease · Lexington, KYNPI 1447543293
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (43.0%), education and travel and lodging — rather than concentrated in one kind of arrangement. 39 manufacturers reported payments, led by Intuitive Surgical at 55.9% of the total. Reporting peaked in 2023 at $9,224 and has fallen 93.0% since, to $644 in 2025.
Across 335 payments — averaging $43.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$8K
- Boehringer Ingelheim$1K
- GSK$795
- Sanofi$627
- AstraZeneca$521
- Genentech USA, Inc.$353
- plus $3K from 33 others
What the payments were for
- Travel & lodging$2,09714%
- Food & beverage$6,22743%
- Education$6,16743%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 7 | $8,097 |
| Boehringer Ingelheim | 72 | $1,195 |
| GSK | 47 | $795 |
| Sanofi | 33 | $627 |
| AstraZeneca | 31 | $521 |
| Genentech USA, Inc. | 13 | $353 |
| Regeneron Healthcare Solutions, Inc. | 19 | $339 |
| Grifols USA, LLC | 17 | $305 |
| AbbVie(2 entities) | 3 | $256 |
| Mylan Specialty L.p. | 12 | $220 |
| Gilead | 12 | $213 |
| Amgen | 10 | $211 |
| Actelion Pharmaceuticals US, Inc. | 5 | $126 |
| Galvanize Therapeutics, Inc | 1 | $113 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Insmed, Inc. | 5 | $100 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $91 |
| Johnson & Johnson | 5 | $88 |
| Novartis | 3 | $64 |
| CSL Behring | 2 | $61 |
| Axsome Therapeutics, Inc. | 2 | $57 |
| United Therapeutics Corporation | 3 | $56 |
| Viatris Specialty LLC | 2 | $53 |
| Vifor Pharma, Inc. | 2 | $49 |
| Abiomed | 2 | $44 |
| Electromed, Inc. | 4 | $43 |
| Merck | 2 | $38 |
| Pulmonx Corporation | 1 | $35 |
| Philips North America LLC | 2 | $32 |
| Paratek Pharmaceuticals, Inc. | 2 | $31 |
| Circassia Inc. | 2 | $31 |
| Jazz Pharmaceuticals Inc. | 1 | $25 |
| Verona Pharma, Inc. | 1 | $23 |
| Inogen, Inc. | 1 | $22 |
| Bayer | 1 | $20 |
| Shire North American Group Inc | 1 | $16 |
| Astellas Pharma US Inc | 1 | $15 |
| Baxter Healthcare | 1 | $14 |
| Mayne Pharma Commercial LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$5,078
- ION$3,000
- TEFLARO$123
- AVYCAZ$115
- ALIYA SYSTEM$113
How this compares
$14,492 in reported general payments places this provider in the 80th percentile of 226 pulmonary disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 24 | $313,442 |
| Dupixent PenDupilumab | 49 | $205,456 |
| NucalaMepolizumab | 39 | $149,979 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 123 | $105,678 |
| Dupixent SyringeDupilumab | 23 | $94,621 |
| TezspireTezepelumab-Ekko | 18 | $78,020 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 66 | $63,398 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 67 | $41,065 |
| Breo ElliptaFluticasone/Vilanterol | 59 | $25,336 |
| Spiriva RespimatTiotropium Bromide | 17 | $15,882 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 18 | $8,448 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 21 | $3,144 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 119 | $2,616 |
| Ventolin HfaAlbuterol Sulfate | 27 | $2,197 |
| BreynaBudesonide/Formoterol Fumarate | 13 | $1,187 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $1,195 | $370,389108 claims |
| GSKNucala, Trelegy Ellipta, Breo Ellipta, Anoro Ellipta | $795 | $289,440239 claims |
| AstraZenecaTezspire, Breztri Aerosphere | $521 | $141,41884 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 226 pulmonary disease providers in Kentucky.
Other pulmonary disease in Lexington
- Dennis DohertyLexington$103K
- Ashish MaskeyLexington$94K
- Girish NairLexington$86K
- John ThompsonLexington$77K
- Anthony GerberLexington$20K
- Eliseo Colon-CarrerasLexington$17K
- Christopher MeenachLexington$15K
- John McConnellLouisville$864K
- Erica GregonisRichmond$390K
- Firas KouraGeorgetown$350K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.